June 02, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
The FDA approved Zaynich as an intravenous treatment for complicated urinary tract infections, including pyelonephritis, in adults, according to a press release from the antibiotic’s manufacturer, Wockhardt.“The threat of drug-resistant infections is an escalating crisis, leaving clinicians with fewer tools to treat patients facing these aggressive pathogens. The FDA approval of
June 02, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of…

Wockhardts newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according…

Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract…

Wockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be…

Wockhardt will be in focus after the US FDA approved ZAYNICH, a novel intravenous antibiotic combining cefepime and zidebactam…

Zaynich (cefepime and zidebactam) is an injectable antibiotic comprising cefepime, a cephalosporin antibacterial drug and…

Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis

FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market